Institut de Recherche pour le Développement (IRD), Unité Mixte de Recherche IRD-CIRAD 177, Campus International de Baillarguet, Montpellier, France.
Parasite Immunol. 2011 Aug;33(8):438-47. doi: 10.1111/j.1365-3024.2011.01287.x.
Since first identified, human African trypanosomiasis (HAT) or sleeping sickness has been described as invariably fatal. Increasing data however argue that infection by Trypanosoma brucei gambiense, the causative agent of HAT, results in a wide range of outcomes in its human host and importantly that a number of subjects in endemic areas are apparently able to control infection to low levels, undetectable by the classical parasitological tests used in the field. Thus, trypanotolerance seems to occur in humans as has already been described in cattle or in the rodent experimental models of infection. This review focuses on the description of the diversity of outcomes resulting from T. b. gambiense in humans and on the host factors involved. The consequences/impacts on HAT epidemiology resulting from this diversity are also discussed with regard to implementing sustainable HAT control strategies.
自首次发现以来,人类非洲锥虫病(HAT)或昏睡病一直被描述为不治之症。然而,越来越多的数据表明,由冈比亚锥虫引起的 HAT 感染会导致人类宿主出现广泛的结果,重要的是,在流行地区的许多患者显然能够将感染控制在低水平,这是通过现场使用的经典寄生虫学检测方法无法检测到的。因此,正如在牛或啮齿动物感染的实验模型中已经描述的那样,人类似乎也存在锥虫耐受力。这篇综述的重点是描述冈比亚锥虫在人类中引起的不同结果,并讨论涉及的宿主因素。还讨论了这种多样性对 HAT 流行病学的影响,以便实施可持续的 HAT 控制策略。